Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study

OBJECTIVES: Lung cancer is the leading cause of cancer-related deaths worldwide. However, factors associated with the survival of patients with advanced non-small-cell lung cancer (NSCLC) who received only hospice care are largely unclear. In this study, we aimed to determine the prognostic factors correlated with survival in patients with advanced NSCLC who had undergone hospice care only. METHODS: A total of 102 patients with recurrent stage III/IV NSCLC after traditional treatment failure were investigated. Survival was measured from the date of enrollment to December 2019 or the time of death. Tumor tissues were collected, and DNA sequencing was performed to identify somatic mutations. Data on clinical factors of patients were collected and analyzed by univariate and multivariate analyses. Overall survival analysis was conducted using the Kaplan-Meier method. RESULTS: The 6-month, 1-year, and 2-year overall survival rates of the 102 patients with metastatic NSCLC were 17.65%, 3.92%, and 0.98%, respectively. The median overall survival of the 102 patients was 3.15 months. Tumor location in the peripheral lung, epidermal growth factor receptor (EGFR) inhibitor history, low tumor mutation load, adenocarcinoma, and poor performance status score were associated with prolonged survival compared with tumor location in the central lung, no EGFR inhibitor history, high tumor mutation load, squamous cell carcinoma, and good performance status score (p=0.045, p=0.003, p=0.045, p=0.021, and p=0.0003, respectively). CONCLUSIONS: EGFR inhibitor treatment history and tumor mutation load are risk factors for the overall survival of patients with stage III/IV NSCLC who have undergone only hospice care. These results provide a critical clinical basis for further study of nontraditional anti-tumor responses induced by EGFR inhibitors.

Saved in:
Bibliographic Details
Main Authors: Lan,Yan, Zhou,Shuo, Feng,Weihong, Qiao,Ying, Du,Xueming, Li,Fenge
Format: Digital revista
Language:English
Published: Faculdade de Medicina / USP 2021
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322021000100238
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1807-59322021000100238
record_format ojs
spelling oai:scielo:S1807-593220210001002382021-03-22Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective studyLan,YanZhou,ShuoFeng,WeihongQiao,YingDu,XuemingLi,Fenge Lung Cancer Hospice Care EGFR Inhibitor Overall Survival Tumor Mutation OBJECTIVES: Lung cancer is the leading cause of cancer-related deaths worldwide. However, factors associated with the survival of patients with advanced non-small-cell lung cancer (NSCLC) who received only hospice care are largely unclear. In this study, we aimed to determine the prognostic factors correlated with survival in patients with advanced NSCLC who had undergone hospice care only. METHODS: A total of 102 patients with recurrent stage III/IV NSCLC after traditional treatment failure were investigated. Survival was measured from the date of enrollment to December 2019 or the time of death. Tumor tissues were collected, and DNA sequencing was performed to identify somatic mutations. Data on clinical factors of patients were collected and analyzed by univariate and multivariate analyses. Overall survival analysis was conducted using the Kaplan-Meier method. RESULTS: The 6-month, 1-year, and 2-year overall survival rates of the 102 patients with metastatic NSCLC were 17.65%, 3.92%, and 0.98%, respectively. The median overall survival of the 102 patients was 3.15 months. Tumor location in the peripheral lung, epidermal growth factor receptor (EGFR) inhibitor history, low tumor mutation load, adenocarcinoma, and poor performance status score were associated with prolonged survival compared with tumor location in the central lung, no EGFR inhibitor history, high tumor mutation load, squamous cell carcinoma, and good performance status score (p=0.045, p=0.003, p=0.045, p=0.021, and p=0.0003, respectively). CONCLUSIONS: EGFR inhibitor treatment history and tumor mutation load are risk factors for the overall survival of patients with stage III/IV NSCLC who have undergone only hospice care. These results provide a critical clinical basis for further study of nontraditional anti-tumor responses induced by EGFR inhibitors.info:eu-repo/semantics/openAccessFaculdade de Medicina / USPClinics v.76 20212021-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322021000100238en10.6061/clinics/2021/e2251
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Lan,Yan
Zhou,Shuo
Feng,Weihong
Qiao,Ying
Du,Xueming
Li,Fenge
spellingShingle Lan,Yan
Zhou,Shuo
Feng,Weihong
Qiao,Ying
Du,Xueming
Li,Fenge
Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study
author_facet Lan,Yan
Zhou,Shuo
Feng,Weihong
Qiao,Ying
Du,Xueming
Li,Fenge
author_sort Lan,Yan
title Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study
title_short Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study
title_full Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study
title_fullStr Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study
title_full_unstemmed Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study
title_sort association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage iii/iv non-small-cell lung cancer: a retrospective study
description OBJECTIVES: Lung cancer is the leading cause of cancer-related deaths worldwide. However, factors associated with the survival of patients with advanced non-small-cell lung cancer (NSCLC) who received only hospice care are largely unclear. In this study, we aimed to determine the prognostic factors correlated with survival in patients with advanced NSCLC who had undergone hospice care only. METHODS: A total of 102 patients with recurrent stage III/IV NSCLC after traditional treatment failure were investigated. Survival was measured from the date of enrollment to December 2019 or the time of death. Tumor tissues were collected, and DNA sequencing was performed to identify somatic mutations. Data on clinical factors of patients were collected and analyzed by univariate and multivariate analyses. Overall survival analysis was conducted using the Kaplan-Meier method. RESULTS: The 6-month, 1-year, and 2-year overall survival rates of the 102 patients with metastatic NSCLC were 17.65%, 3.92%, and 0.98%, respectively. The median overall survival of the 102 patients was 3.15 months. Tumor location in the peripheral lung, epidermal growth factor receptor (EGFR) inhibitor history, low tumor mutation load, adenocarcinoma, and poor performance status score were associated with prolonged survival compared with tumor location in the central lung, no EGFR inhibitor history, high tumor mutation load, squamous cell carcinoma, and good performance status score (p=0.045, p=0.003, p=0.045, p=0.021, and p=0.0003, respectively). CONCLUSIONS: EGFR inhibitor treatment history and tumor mutation load are risk factors for the overall survival of patients with stage III/IV NSCLC who have undergone only hospice care. These results provide a critical clinical basis for further study of nontraditional anti-tumor responses induced by EGFR inhibitors.
publisher Faculdade de Medicina / USP
publishDate 2021
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322021000100238
work_keys_str_mv AT lanyan associationoftumormutationburdenandepidermalgrowthfactorreceptorinhibitorhistorywithsurvivalinpatientswithmetastaticstageiiiivnonsmallcelllungcanceraretrospectivestudy
AT zhoushuo associationoftumormutationburdenandepidermalgrowthfactorreceptorinhibitorhistorywithsurvivalinpatientswithmetastaticstageiiiivnonsmallcelllungcanceraretrospectivestudy
AT fengweihong associationoftumormutationburdenandepidermalgrowthfactorreceptorinhibitorhistorywithsurvivalinpatientswithmetastaticstageiiiivnonsmallcelllungcanceraretrospectivestudy
AT qiaoying associationoftumormutationburdenandepidermalgrowthfactorreceptorinhibitorhistorywithsurvivalinpatientswithmetastaticstageiiiivnonsmallcelllungcanceraretrospectivestudy
AT duxueming associationoftumormutationburdenandepidermalgrowthfactorreceptorinhibitorhistorywithsurvivalinpatientswithmetastaticstageiiiivnonsmallcelllungcanceraretrospectivestudy
AT lifenge associationoftumormutationburdenandepidermalgrowthfactorreceptorinhibitorhistorywithsurvivalinpatientswithmetastaticstageiiiivnonsmallcelllungcanceraretrospectivestudy
_version_ 1756432381228613632